Cutaneous Squamous Cell Carcinoma (cSCC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035
Cutaneous
Squamous Cell Carcinoma (cSCC) Market Outlook
Thelansis’s “Cutaneous Squamous
Cell Carcinoma (cSCC) Market Outlook, Epidemiology, Competitive Landscape, and
Market Forecast Report – 2025 To 2035” covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Cutaneous
Squamous Cell Carcinoma (cSCC) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Cutaneous
Squamous Cell Carcinoma (cSCC) Overview
Cutaneous squamous cell carcinoma
(cSCC) is the second most common skin cancer, arising from malignant
transformation of epidermal keratinocytes driven predominantly by cumulative
ultraviolet radiation-induced DNA damage, with additional risk factors including
immunosuppression, chronic wounds, human papillomavirus infection, arsenic
exposure, and inherited conditions including xeroderma pigmentosum. Somatic
mutations in TP53, CDKN2A, NOTCH1, and HRAS alongside high tumour mutational
burden characterise the genomic landscape. The majority of cSCCs are localised
and curable with surgical excision, however high-risk features including tumour
diameter exceeding 2cm, poor differentiation, perineural invasion, deep tissue
invasion, and immunosuppressed host status confer elevated recurrence and
metastatic risk warranting multidisciplinary evaluation. Diagnosis is
established by excisional or incisional biopsy with histopathological
assessment; sentinel lymph node biopsy and cross-sectional imaging address regional
and distant staging in high-risk disease. Surgical excision with appropriate
margins remains the cornerstone of localised disease management, with Mohs
micrographic surgery offering superior margin control for high-risk facial and
anatomically sensitive lesions. Adjuvant radiotherapy addresses high-risk
resected disease with adverse pathological features. Cemiplimab, an anti-PD-1
checkpoint inhibitor, is the established standard of care for locally advanced
unresectable or metastatic cSCC, delivering durable responses and meaningful
survival benefit. Pembrolizumab provides an approved alternative in eligible
patients. Prognosis is excellent for localised disease; immunosuppressed
patients warrant intensified surveillance given substantially elevated recurrence
and progression risk, with multidisciplinary skin cancer team involvement
integral to high-risk disease management.
Geography
coverage:
G8 (United
States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights
driven by robust research, including:
- In-depth interviews with leading KOLs
and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based
automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets
and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the most
promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment